SEC Form 10-Q filed by Journey Medical Corporation
Unavailable
Unavailable
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/22/2024 | $9.00 | Buy | Rodman & Renshaw |
6/28/2024 | $11.00 | Buy | ROTH MKM |
2/25/2022 | $9.00 | Overweight | Cantor Fitzgerald |
12/16/2021 | $15.00 | Buy | Roth Capital |
12/7/2021 | $14.00 | Buy | B. Riley Securities |
4 - Journey Medical Corp (0001867066) (Issuer)
4 - Journey Medical Corp (0001867066) (Issuer)
4 - Journey Medical Corp (0001867066) (Issuer)
SC 13G/A - Journey Medical Corp (0001867066) (Subject)
SC 13G - Journey Medical Corp (0001867066) (Subject)
SC 13G - Journey Medical Corp (0001867066) (Subject)
10-Q - Journey Medical Corp (0001867066) (Filer)
8-K - Journey Medical Corp (0001867066) (Filer)
8-K - Journey Medical Corp (0001867066) (Filer)
4 - Journey Medical Corp (0001867066) (Issuer)
4 - Journey Medical Corp (0001867066) (Issuer)
4 - Journey Medical Corp (0001867066) (Issuer)
U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of 2025 Total revenues for the third quarter ended September 30, 2024 were $14.6 million SCOTTSDALE, Ariz., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results a
SCOTTSDALE, Ariz., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the FDA has approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg), formerly referred to as DFD-29, for the treatment of inflammatory lesions of rosacea in adults. Emrosi was developed in collaboration with Dr. Reddy's Laboratories Ltd. Claude Maraoui, Co-Founder, President, and Chief Executive Officer of Jo
Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral Doxycycline 40 mg Capsules (Oracea®) in Healthy Subjects With its modified-release formulation, DFD-29 (40 mg) provides higher dermal concentration than doxycycline from Day 1 onward at a similar dose, expected to translate into a clinically meaningful impact for treating patients with rosacea New Drug Application for DFD-29 under review by FDA with PDUFA goal date of November 4, 2024 SCOTTSDALE, Ariz., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that
Rodman & Renshaw initiated coverage of Journey Medical with a rating of Buy and set a new price target of $9.00
ROTH MKM resumed coverage of Journey Medical with a rating of Buy and set a new price target of $11.00
Cantor Fitzgerald initiated coverage of Journey Medical with a rating of Overweight and set a new price target of $9.00
SCOTTSDALE, Ariz., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the FDA has approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg), formerly referred to as DFD-29, for the treatment of inflammatory lesions of rosacea in adults. Emrosi was developed in collaboration with Dr. Reddy's Laboratories Ltd. Claude Maraoui, Co-Founder, President, and Chief Executive Officer of Jo
Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule.The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m. Central Time on November 15, 2024, to discuss the company's financial results for the quarter. Call details will be available in the quarterly results
New Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of November 4, 2024 Total revenues for the second quarter ended June 30, 2024 were $14.9 million, a 14% increase from the $13.0 million reported in the first quarter of 2024 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for
SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that on July 9, 2024, it appointed Michael C. Pearce to its Board of Directors. Mr. Pearce is a principal investor with an emphasis on healthcare. Since 2015, he has served as an advisor to EP Group and board member of its predecessor parent company, Evening Post Industries ("EPI"). At EPI, he served on the audit, compensation, and inves
SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the appointment of Joseph M. Benesch as Chief Financial Officer, effective April 26, 2024. Mr. Benesch had served as the Company's Interim Chief Financial Officer since January 2023 and he served as the Company's Corporate Controller prior to that since November 2021. Claude Maraoui, Co-Founder, President and Chief
REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced the appointment of Thomas G. Wiggans, a veteran biopharmaceutical executive, as Chairperson of Jasper's Board of Directors (the Board), effective immediately. Bill Lis is stepping down as Chairperson and will re
Roth MKM analyst Jason Wittes reinstates Journey Medical (NASDAQ:DERM) with a Buy and announces $11 price target.
Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) fell sharply during Monday's session after the company announced its SBI-100 Ophthalmic Emulsion Phase 2a trial did not achieve target product profile and has discontinued the program. Skye Bioscience shares tumbled 18.9% to $8.87 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Big Tree Cloud Holdings Limited (NASDAQ:DSY) shares jumped 123% to $4.3001 following the completion of the company’s business combination with Plutonian Acquisition Corp. and amid continued volatility following its Nasdaq debut last week. KWESST Micro Systems Inc. (NASDAQ:KWE) gained 79.8% to $0.7082 after the company was aw
Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.23) by 130.43 percent. The company reported quarterly sales of $13.000 million which missed the analyst consensus estimate of $14.098 million by 7.79 percent. This is a 6.44 percent increase over sales of $12.213 million the same period last year.